- Home
- Publications
- Publication Search
- Publication Details
Title
Polycythemia vera treatment algorithm 2018
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-10
DOI
10.1038/s41408-017-0042-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
- (2017) Guilin Tang et al. HAEMATOLOGICA
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
- (2017) Tiziano Barbui et al. HAEMATOLOGICA
- Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
- (2017) Guilin Tang et al. HAEMATOLOGICA
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
- (2017) Tiziano Barbui et al. HAEMATOLOGICA
- Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
- (2016) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
- (2016) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
- (2016) Brianna E. Vaa et al. ANNALS OF HEMATOLOGY
- The Rap1-RIAM-talin axis of integrin activation and blood cell function
- (2016) F. Lagarrigue et al. BLOOD
- Somatic JAK2 mutations and their tumor phenotypes
- (2016) Ayalew Tefferi BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib
- (2016) Keita Kirito et al. INTERNAL MEDICINE
- Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
- (2016) Genevieve Douglas et al. LEUKEMIA & LYMPHOMA
- Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
- (2016) K Begna et al. Blood Cancer Journal
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
- (2015) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
- (2015) Nicole C.C. Them et al. AMERICAN JOURNAL OF HEMATOLOGY
- Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
- (2015) Juan-Carlos Hernández-Boluda et al. ANNALS OF HEMATOLOGY
- White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
- (2015) T. Barbui et al. BLOOD
- Detection of mutations inJAK2exons 12-15 by Sanger sequencing
- (2015) N. Alghasham et al. International Journal of Laboratory Hematology
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
- (2015) S Cerquozzi et al. Blood Cancer Journal
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
- (2014) T. Barbui et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis
- (2014) Marina Kremyanskaya et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
- (2013) Fabian P. Siegel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
- (2012) T. Barbui et al. BLOOD
- Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
- (2012) Gilles Bonicelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
- (2012) Malin Hultcrantz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia
- (2011) Jean-Guillaume Dillinger et al. THROMBOSIS RESEARCH
- Polycythemia vera and pregnancy: experience of four pregnancies in a single patient
- (2010) Neelam Aggarwal et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations
- (2009) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
- (2008) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
- (2008) V. De Stefano et al. HAEMATOLOGICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started